Divis Laboratories Ltd (DIVISLAB)

Divis Laboratories Explores Growth Avenues Amid Pricing Pressure - 20 Jul, 2024

Divis Laboratories is expected to expand its portfolio of generic APIs and launch seven more molecules in the next three years. The company has made headway in the small organic molecule space with GLP-1 products, but faces pricing pressure in the business. Valuations are at a premium, trading at 55 times one-year forward earnings. While growth outlook is strong, high expectations will have to temper down before investing.

Divis Labs Beats Expectations, Completes USFDA Inspection - 19 Jul, 2024

Divis Laboratories beat revenue and EPS expectations in its full-year report. The company's Unit II manufacturing facility passed a USFDA inspection with one procedural observation.

CDMO Business Gaining Traction in Indian Pharma Industry - 16 Jul, 2024

Indian pharmaceutical companies, including Divis Laboratories and Laurus Labs, are expanding their CDMO capacities as the business gains traction. Piramal Pharma's CDMO business is also growing, while Suven Pharma and JB Chemicals & Pharmaceuticals have plans to expand theirs. New contracts could help Laurus Labs utilize its capacities better.

Divis Laboratories Insiders Sell Substantial Stake - 14 Jul, 2024

Insiders in Divis Laboratories have sold a significant stake in the company over the last year, with no insider buying. The insiders own 49% of the company's shares worth about ₹593b.

Divis Laboratories Could Benefit from US Reducing Dependence on China for API Manufacturing - 10 Jul, 2024

According to market analyst Mukherjea, the US reducing its dependence on China for API manufacturing could benefit Indian pharma companies like Divis Laboratories. If India captures just 10% of China's market share, the Indian API industry could double in size within three years. Additionally, there is a shortage of contrast media in the US, which large pharma companies may turn to Divis Laboratories for.

Divis Laboratories Q1FY25 Net Profit Expected to Grow 43.7% - 09 Jul, 2024

According to MOFSL, Divis Laboratories is expected to see a YoY net profit growth of 43.7% in Q1FY25 to ₹512.7 crore and a net sales increase of 23.7% to ₹2,199.4 crore due to good traction in CS, supported by growth in Nutraceutical and generics business. EBITDA is also predicted to increase 35.3% to ₹682 crore.

Divis Laboratories Share Price Soars 183% in Last Five Years - 22 Jun, 2024

Despite growing earnings per share at a slower rate than the increase in share price, Divis Laboratories has seen a TSR of 194% over the last five years. The company's high P/E ratio of 86.78 reflects market optimism and dividends have boosted total shareholder return.